{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:16:21Z","timestamp":1780614981197,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PEDEMO20G0"],"award-info":[{"award-number":["PEDEMO20G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018\u201312367126"],"award-info":[{"award-number":["GR-2018\u201312367126"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T15:31:09Z","timestamp":1671463869000},"page":"525-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-1916","authenticated-orcid":false,"given":"Valeria","family":"Tomati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Capurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8565-4393","authenticated-orcid":false,"given":"Cristina","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-2885","authenticated-orcid":false,"given":"Mariateresa","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-2082","authenticated-orcid":false,"given":"Elvira","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-5374","authenticated-orcid":false,"given":"Federico","family":"Cresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cristadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-3461","authenticated-orcid":false,"given":"Luis J.V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Bocciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-0963","authenticated-orcid":false,"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Lucanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcf.2022.12.005_bib0002","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: the Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0004","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1152\/physrev.00007.2018","article-title":"Structure, Gating, and Regulation of the Cftr Anion Channel","volume":"99","author":"Csanady","year":"2019","journal-title":"Physiol Rev"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1515\/hsz-2018-0470","article-title":"CFTR structure, stability, function and regulation","volume":"400","author":"Meng","year":"2019","journal-title":"Biol Chem"},{"issue":"8","key":"10.1016\/j.jcf.2022.12.005_bib0006","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.005_bib0007","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ajmg.a.20038","article-title":"1154insTC is not a rare CFTR mutation","volume":"120A","author":"Alper","year":"2003","journal-title":"Am J Med Genet A"},{"issue":"31","key":"10.1016\/j.jcf.2022.12.005_bib0008","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","article-title":"Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation","volume":"274","author":"Haardt","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.005_bib0009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"5993","key":"10.1016\/j.jcf.2022.12.005_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2022.12.005_bib0012","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.jcf.2022.12.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"issue":"6617","key":"10.1016\/j.jcf.2022.12.005_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of Delta508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.005_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105262","article-title":"Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10212","key":"10.1016\/j.jcf.2022.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2022.12.005_bib0018","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2S","key":"10.1016\/j.jcf.2022.12.005_bib0019","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcf.2017.08.013","article-title":"Therapeutic approaches to CFTR dysfunction: from discovery to drug development","volume":"17","author":"Li","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fphar.2018.01100","article-title":"Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer","volume":"9","author":"Fukuda","year":"2018","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.005_bib0021","first-page":"1127","article-title":"Screening for non-delta F508 mutations in five exons of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in Italy","volume":"48","author":"Devoto","year":"1991","journal-title":"Am J Hum Genet"},{"issue":"5077","key":"10.1016\/j.jcf.2022.12.005_bib0022","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1126\/science.1382316","article-title":"Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains","volume":"257","author":"Anderson","year":"1992","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.005_bib0023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1085\/jgp.201711946","article-title":"Structural mechanisms of CFTR function and dysfunction","volume":"150","author":"Hwang","year":"2018","journal-title":"J Gen Physiol"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.005_bib0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.005_bib0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.10.011","article-title":"Mutation-specific dual potentiators maximize rescue of CFTR gating mutants","volume":"19","author":"Veit","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.005_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients: the Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jcf.2022.12.005_bib0027","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI0216112","article-title":"Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion","volume":"110","author":"Ma","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2022.12.005_bib0028","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator","author":"Laselva","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.005_bib0029","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2022.12.005_bib0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","article-title":"Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia","volume":"25","author":"Sondo","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.005_bib0032","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0033","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/s41467-022-31854-8","article-title":"A multimodal iPSC platform for cystic fibrosis drug testing","volume":"13","author":"Berical","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.005_bib0034","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jcf.2017.09.005","article-title":"Recent progress in translational cystic fibrosis research using precision medicine strategies","volume":"17","author":"Cholon","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2022.12.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102210","article-title":"Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics","volume":"64","author":"Cholon","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"24","key":"10.1016\/j.jcf.2022.12.005_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413196","article-title":"Revisiting CFTR Interactions: old Partners and New Players","volume":"22","author":"Farinha","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.005_bib0037","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/1381612822666161006161033","article-title":"RNF5, DAB2 and Friends: novel Drug Targets for Cystic Fibrosis","volume":"23","author":"Sondo","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.005_bib0038","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","article-title":"DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers","volume":"23","author":"Rowe","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jcf.2022.12.005_bib0039","doi-asserted-by":"crossref","first-page":"eaay9669","DOI":"10.1126\/sciadv.aay9669","article-title":"Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel","volume":"6","author":"Pedemonte","year":"2020","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.005_bib0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2018.05.010","article-title":"Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators","volume":"17","author":"Phuan","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.12.005_bib0041","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3389\/fphar.2018.01176","article-title":"In vitro Methods for the Development and Analysis of Human Primary Airway Epithelia","volume":"9","author":"Gianotti","year":"2018","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.005_bib0042","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","article-title":"Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells","volume":"19","author":"Mou","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.005_bib0043","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.005_bib0044","doi-asserted-by":"crossref","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.005_bib0045","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1074\/jbc.M117.816595","article-title":"High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel","volume":"293","author":"Tomati","year":"2018","journal-title":"J Biol Chem"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:11Z","timestamp":1761601691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322014254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199322014254"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}